linjc16/ctgov huggingface dataset:
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Study Overview
=================
Brief Summary
-----------------
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC

Official Title
-----------------
A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Radiation: modified reduce-volume target IMRT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma; Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT; Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital; Diagnosis time: November 1, 2014 to December 31 , 2017 Exclusion Criteria: Disease progression during IMRT; Previous malignancy or other concomitant malignant diseases; The evaluation information of tumor efficacy can not be obtained; Receive blind treatment in other clinical research.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Modified reduce-volume target IMRT<br>Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT | Radiation: modified reduce-volume target IMRT<br>* The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local failure-free survival (LFFS) | The duration of time to LFFS was calculated from the date of histological diagnosis until documented treatment local failure. | 60 month |
The Research of Human Cortex Cell Atlas

Study Overview
=================
Brief Summary
-----------------
In this study, the single-cell transcriptome sequencing technology was used to study the transcriptome differences at the single-cell level in normal human brain, aging human brain, and epileptic brain.

Detailed Description
-----------------
The human brain has about 100 billion cells and makes up neural networks.The abnormal activity of neurons can affect the operation of neural networks, leading to neurological diseases.With the coming of the age of global population aging, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's have become an increasing burden on human health. Cells are the basic unit of brain. Understanding the mechanism of brain activities includes not only the mechanism of neural network, but also the self-regulation of its basic unit, that is, the regulation of gene expression based on brain activity.The abnormal expression and regulation of genes lead to the abnormal activities of the nervous system.Therefore, studying the regulation mechanism of gene expression at the cellular level is an important way to research brain diseases.The recent development of single-cell RNA-sequencing technology provides a possibility to understand the functioning mechanism of the brain at the cellular level.

Official Title
-----------------
The Research of Human Cortex Cell Atlas

Conditions
-----------------
Aging, Epilepsy, Trauma, Brain

Intervention / Treatment
-----------------
* Other: brain tissue single-cell sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Craniocerebral injury patients needing operative treatment Treatment-resistant epilepsy patients needing resection surgery Exclusion Criteria: Vital signs unstable Pregnancy Tumor Incomplete medical history, imaging and clinical diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| single-cell RNA sequencing | single-cell RNA sequencing resultes of brain sample | 1 Day of surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Single-Cell Analysis, aging, epilepsy, trauma brain
Dual Rapid HIV & Syphilis Tests in Zambia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide evidence on the performance and operational characteristics of commercially available dual HIV/syphilis Rapid Diagnostic Tests (RDTs) in Zambia for their introduction into antenatal care and other settings.

Detailed Description
-----------------
Early detection and timely intervention of pregnant women infected with HIV and/or syphilis is critical. To improve the number of women tested and treated, the Centre for Infectious Disease Research in Zambia (CIDRZ) and the Ministry of Community Development, Mother and Health (MCDMCH) this field study will assess the effectiveness of newly developed dual HIV and syphilis rapid diagnostic tests (RDTs) manufactured by Chembio and Standard Diagnostics in Lusaka District antenatal clinics. The specific objectives of this field performance evaluation of the rapid diagnostics are to determine the antenatal clinic-based performance of dual HIV/syphilis RDTs compared to that of current reference standard assays, and to assess the operational characteristics and acceptability of these dual HIV/syphilis RDTs to patients and health care providers This cross-sectional study of 3,765 pregnant women will validate the performance of Chembio and Standard Diagnostics dual HIV and Syphilis RDTs.

Official Title
-----------------
Field Performance Evaluation of Dual Rapid HIV & Syphilis Tests in Zambia

Conditions
-----------------
HIV, Syphilis

Intervention / Treatment
-----------------
* Device: dual HIV/syphilis rapid diagnostics tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women attending their first antenatal care visit at a study clinic 18 years of age or older Willing and able to provide informed consent for study participation Exclusion Criteria: Prior participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women<br>Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia | Device: dual HIV/syphilis rapid diagnostics tests<br> <br> * Other names: Chembio and Standard Disgnostics;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| performance of dual rapid HIV/syphilis tests | The performance of the rapid study tests will be assessed by determining the specificity and the sensitivity when compared to reference standard assays | day 1/enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acceptability of use of dual rapid HIV/syphilis tests | the operational characteristics and acceptability of the tests to patients and health care providers will be measured. | day 1/enrollment |
Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.

Study Overview
=================
Brief Summary
-----------------
Healthy toddlers (age 9-18 month) following a routine blood count will be placed in three groups: Iron deficiency with no anemia anemia no anemia and no iron deficiency Following a nutritional questionnaire, parents of all toddlers will receive instruction regarding appropriate nutrition in the 2nd year of life. Groups 1 and 2 will randomly receive one of two preparations currently in use for treatment of iron deficiency in Israel (Aktiron 35 - Ferrous gluconate and Ferripel-3 - iron polysaccharide complex). Followup blood count will be taken 3 month after recruitment. The study aims to compare the effectiveness of the Iron preparations regarding compliance and efficacy. The hypothesis is that a significant difference will be detected between the two preparations.

Conditions
-----------------
Iron Deficiency, Anemia

Intervention / Treatment
-----------------
* Drug: Ferrous gluconate and iron polysaccharide complex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy toddlers age 9-18 months Exclusion Criteria: Toddlers with: chronic diseases, prematurity, inherited hematological disease.

Ages Eligible for Study
-----------------
Minimum Age: 9 Months
Maximum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin |  | 3 months |
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Study Overview
=================
Brief Summary
-----------------
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).

Official Title
-----------------
A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis

Conditions
-----------------
Secondary Hyperparathyroidism

Intervention / Treatment
-----------------
* Drug: Hectorol (doxercalciferol injection)
* Drug: Zemplar (Paricalcitol injection)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject must be receiving hemodialysis three times per week for a minimum of three months. The subject must be receiving intravenous doxercalciferol or paricalcitol at each dialysis session (three times weekly) for a minimum of 12 weeks prior to Screening. At Screening Visit the subject's laboratory measurements must be within the following ranges: Serum iPTH measurement between 150-800 pg/mL; Corrected calcium measurement ≤ 10.5 mg/dL; Serum phosphorus measurement ≤ 7 mg/dL Exclusion Criteria: Any ongoing use of over the counter or prescription vitamin D preparations except doxercalciferol or paricalcitol injection or multivitamins. History of heparin-induced thrombocytopenia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Hectorol (doxercalciferol injection)|nan|
|Drug: Zemplar (Paricalcitol injection)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic Study |  | 44 hour interval | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hectorol (doxercalciferol injection), Zemplar (paricalcitol injection)
Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel

Study Overview
=================
Brief Summary
-----------------
The study aims to validate a Food Frequency Questionnaire (FFQ) designed specifically for the vegan population in Israel. The participants will complete the FFQ, and the data will be verified by evaluating the participants energy expenditure (by measuring BMR, body composition and daily activity) and conducting a 24-hour food interview.

Official Title
-----------------
Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel

Conditions
-----------------
Vegan Diet

Intervention / Treatment
-----------------
* Other: Food Frequency Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consumption of beef, chicken, fish, eggs, milk or dairy is no more than once a month, for the last 6 months age 18-40 Exclusion Criteria: consumption of beef, chicken, fish, eggs, milk or dairy more than once a month chronic conditions (such as diabetes, hypertension, cardiovascular disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Food Frequency Questionnaires<br>Filling out a Food Frequency Questionnaires (FFQ) | Other: Food Frequency Questionnaires<br>* filling a Food Frequency Questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily energy consumption (Kcal/Day) |  | 24 hour |
Gait Control of Stroke Patients Using Visual Feedback

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the possibility of gait pattern change via visual feedback among patients with stroke. Also, the optimal visual feedback would be chosen from this study.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Visual distortion increment based on the gait pattern


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemiplegic stroke patients >= 18 years old Functional Ambulation Category >=3 Cognitively intact enough to follow the study protocol Adults without any gait problem Exclusion Criteria: Quadriplegic stroke patients Orthopedic problems to affect gait Underlying other neurological or psychological disorders Spasticity or contracture which impede the gait. Uncontrolled medical problems Pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Visual feedback distortion<br>Visual distortion increment based on the gait pattern | Device: Visual distortion increment based on the gait pattern<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Step length symmetry | Step length symmetry during treadmill gait. When the participants walk on the treadmill, the walk symmetry was calculated from the sensor attached to them. During the whole period of treadmill gait, step length asymmetry will be recorded. | Participants will be followed for the duration of treadmill gait, an expected average of 15 minutes |
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

Official Title
-----------------
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: Glatiramer acetate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsing-remitting (RR) MS patients (McDonald criteria) Ages 18-55 Males and females EDSS score ≤5 No prior treatment with Copaxone Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month Exclusion Criteria: Treatment with Tysabri, Novantrone or cyclophosphamide Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate) Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RRMS<br>Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care | Drug: Glatiramer acetate<br>* 20 mg daily subcutaneous injection. Six-month duration.<br>* Other names: Copaxone;|
| HC<br>Healthy control volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Production of inflammatory cytokines by monocytes and naive T cells. |  | 0, 1, 2, 4, 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
relapsing-remitting, multiple sclerosis, Copaxone, glatiramer acetate, MS
The Endoscopic Assesment of Intestinal Grafts

Study Overview
=================
Brief Summary
-----------------
The study validates prospectively a new endoscopic scoring system (Gothenburg Intestinal Transplant Endoscopy Score, GITES) designed to summarize and stratify the abnormal ileal endoscopic findings after intestinal transplantation. GITES is a five-tier, four grade score which asseses mucosal friability, mucosal erythema and mucosal injury (ulcerations) as well as villous changes according to severity. These features (i.e., endoscopic descriptors) are also grouped from mild to very severe in the same sequence as observed during the progression of several pathologic conditions encountered after intestinal transplantation (acute rejection, infectious enteritis).

Official Title
-----------------
A Multi-centre, Longitudinal (Cohort) Study in Patients Undergoing Intestinal or Multivisceral Transplantation to Validate Gothenburg Intestinal Transplant Endoscopy Score (GITES) and Evaluate Its Clinical Performance

Conditions
-----------------
Transplant; Complication, Rejection, Transplant; Intestine, Transplant; Failure, Bowel, Enteritis, Mucosal Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: transplantation of a segment of small intestine (as isolated graft or together with other organs) Exclusion Criteria: contraindications for ileoscopy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endoscopic evaluation | To validate the GITES grading system in intestinal graft recipients using high-definition white light endoscopy | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlations with histology and Clinical course | Comparison and correlation of clinical and histopathological data with endoscopic findings to evaluate the conditions leading to the mucosal alterations defined by established endoscopic descriptors and GITES. | 1 year | 
| Performance of the grading score | Endpoints include sensitivity, specificity, positive predictive value, negative predictive value as well as inter- and intraobserver variation in the evaluation of the mucosal alterations by means of GITES and using high-definition white light endoscopy; | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transplantation; intestine, endoscopy, severity score, transplant rejection, transplant; complications